PL2978455T3 - Semifluorowęglowodorowy związek zawierający środek kontrastowy - Google Patents

Semifluorowęglowodorowy związek zawierający środek kontrastowy

Info

Publication number
PL2978455T3
PL2978455T3 PL14710891T PL14710891T PL2978455T3 PL 2978455 T3 PL2978455 T3 PL 2978455T3 PL 14710891 T PL14710891 T PL 14710891T PL 14710891 T PL14710891 T PL 14710891T PL 2978455 T3 PL2978455 T3 PL 2978455T3
Authority
PL
Poland
Prior art keywords
semifluorocarbon
compound containing
contrast agent
containing contrast
agent
Prior art date
Application number
PL14710891T
Other languages
English (en)
Inventor
Thorsten Keller
Doris Röthlein
Jürgen Schmitt
Thore Dietrich
Philipp Stawowy
Eckart Fleck
Original Assignee
B. Braun Melsungen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B. Braun Melsungen Ag filed Critical B. Braun Melsungen Ag
Publication of PL2978455T3 publication Critical patent/PL2978455T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806Suspensions, emulsions, colloids, dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/05Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01RMEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00Arrangements or instruments for measuring magnetic variables
    • G01R33/20Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48NMR imaging systems
    • G01R33/54Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Signal Processing (AREA)
  • Pathology (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
PL14710891T 2013-03-25 2014-03-18 Semifluorowęglowodorowy związek zawierający środek kontrastowy PL2978455T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13160868.9A EP2783703A1 (en) 2013-03-25 2013-03-25 Semifluorocarbon compound containing contrast agent
EP14710891.4A EP2978455B1 (en) 2013-03-25 2014-03-18 Semifluorocarbon compound containing contrast agent

Publications (1)

Publication Number Publication Date
PL2978455T3 true PL2978455T3 (pl) 2017-06-30

Family

ID=47913282

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14710891T PL2978455T3 (pl) 2013-03-25 2014-03-18 Semifluorowęglowodorowy związek zawierający środek kontrastowy

Country Status (17)

Country Link
US (2) US20160000941A1 (pl)
EP (2) EP2783703A1 (pl)
JP (1) JP6356780B2 (pl)
KR (1) KR102210774B1 (pl)
CN (1) CN105142681B (pl)
BR (1) BR112015017572A2 (pl)
CA (1) CA2893799C (pl)
DK (1) DK2978455T3 (pl)
ES (1) ES2616884T3 (pl)
HU (1) HUE030818T2 (pl)
IL (1) IL239203A (pl)
MX (1) MX362702B (pl)
PL (1) PL2978455T3 (pl)
PT (1) PT2978455T (pl)
RU (1) RU2672588C2 (pl)
TW (1) TWI652069B (pl)
WO (1) WO2014154531A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102869345B (zh) 2010-03-17 2015-02-11 诺瓦利克有限责任公司 用于治疗眼内压增高的药物组合物
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
PL2714010T3 (pl) 2011-05-25 2017-08-31 Novaliq Gmbh Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach
AU2013211645B2 (en) 2012-01-23 2017-06-15 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
EP2895158B1 (en) 2012-09-12 2019-11-20 Novaliq GmbH Compositions comprising mixtures of semifluorinated alkanes
EP3181119B1 (en) 2012-09-12 2019-07-10 Novaliq GmbH Semifluorinated alkane compositions for use in the treatment of keratoconjunctivitis sicca
JP6503349B2 (ja) 2013-07-23 2019-04-17 ノバリック ゲーエムベーハー 安定化された抗体組成物
DE202016008739U1 (de) 2015-09-30 2019-04-29 Novaliq Gmbh Semifluorierte Verbindungen
PT3355990T (pt) 2015-09-30 2019-09-11 Novaliq Gmbh Compostos semifluorados e as suas composições
EP3203256A1 (en) 2016-02-02 2017-08-09 B. Braun Melsungen AG Calibration of mri systems using pre-defined concentrations of 19f isotopes as reference
KR102257916B1 (ko) 2016-06-23 2021-05-28 노바리크 게엠베하 드롭 디스펜서를 포함하는 키트
CN109890374A (zh) 2016-09-22 2019-06-14 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
JP6869336B2 (ja) 2016-09-23 2021-05-12 ノバリック ゲーエムベーハー シクロスポリンを含む眼科用組成物
WO2018193093A1 (en) 2017-04-21 2018-10-25 Novaliq Gmbh Iodine compositions
WO2018202835A1 (en) 2017-05-05 2018-11-08 Novaliq Gmbh Process for the production of semifluorinated alkanes
CN110650734A (zh) 2017-05-12 2020-01-03 诺瓦利克有限责任公司 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
AU2019345929B2 (en) 2018-09-27 2022-02-03 Dermaliq Therapeutics, Inc. Topical sunscreen formulation
CN112823020A (zh) 2018-10-12 2021-05-18 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
RU2723391C1 (ru) * 2019-09-19 2020-06-11 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ определения тромбоза ушка левого предсердия по данным контрастной трансторакальной эхокардиографии

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0231091B1 (en) 1986-01-24 1993-03-31 Children's Hospital Medical Center Stable emulsions of highly fluorinated organic compound
US5171755A (en) * 1988-04-29 1992-12-15 Hemagen/Pfc Emulsions of highly fluorinated organic compounds
DE4405627A1 (de) * 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US7220401B2 (en) * 1999-09-24 2007-05-22 Barnes-Jewish Hospital Blood clot-targeted nanoparticles
IL163937A0 (en) 2002-03-07 2005-12-18 Univ Carnegie Mellon Contrast agents for magnetic resonance imaging andmethods realted thereto
EP1713513B1 (en) * 2004-01-16 2014-06-04 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
RU2262920C1 (ru) * 2004-09-28 2005-10-27 Открытое Акционерное Общество "Фаберлик" Водная эмульсия перфторсоединений для косметических и/или дерматологических препаратов и способ ее получения
EP1885243A4 (en) 2005-05-11 2014-05-21 Univ Minnesota METHODS AND DEVICE FOR REPRESENTING MAGNETIC INDUCTION
DE102007015598A1 (de) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
CN102869345B (zh) * 2010-03-17 2015-02-11 诺瓦利克有限责任公司 用于治疗眼内压增高的药物组合物
PT2661280T (pt) 2011-01-04 2019-02-25 Novaliq Gmbh Emulsões o/a compreendendo alcanos semifluorados
WO2013158265A1 (en) * 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy

Also Published As

Publication number Publication date
CA2893799C (en) 2021-03-09
US20160000941A1 (en) 2016-01-07
IL239203A (en) 2017-03-30
US20230355810A1 (en) 2023-11-09
PT2978455T (pt) 2017-02-24
MX362702B (es) 2019-02-01
KR102210774B1 (ko) 2021-02-02
EP2978455A1 (en) 2016-02-03
JP2016515553A (ja) 2016-05-30
MX2015013746A (es) 2016-02-26
EP2978455B1 (en) 2017-01-04
RU2672588C2 (ru) 2018-11-16
HUE030818T2 (en) 2017-06-28
BR112015017572A2 (pt) 2017-07-11
WO2014154531A1 (en) 2014-10-02
ES2616884T3 (es) 2017-06-14
IL239203A0 (en) 2015-07-30
CN105142681B (zh) 2019-03-12
RU2015130915A3 (pl) 2018-03-19
TWI652069B (zh) 2019-03-01
CN105142681A (zh) 2015-12-09
CA2893799A1 (en) 2014-10-02
KR20150132836A (ko) 2015-11-26
DK2978455T3 (en) 2017-03-06
RU2015130915A (ru) 2017-04-27
TW201524521A (zh) 2015-07-01
JP6356780B2 (ja) 2018-07-11
EP2783703A1 (en) 2014-10-01

Similar Documents

Publication Publication Date Title
IL249518A0 (en) A compound that inhibits trk
IL239203A0 (en) A semifluorocarbon compound containing a contrast agent
AP2015008713A0 (en) Tetrahydropyrrolothiazine compounds
GB201309085D0 (en) Compounds
GB201302927D0 (en) Compounds
GB201302368D0 (en) Compound
GB201311951D0 (en) Compounds
HK1219100A1 (zh) 吡啶基吡唑並喹啉化合物
AP3850A (en) Azetidinyloxyphenylpyrrolidine compounds
EP2947066A4 (en) PHENOXYALKYLAMINVERBINDUNG
EP3010923A4 (en) PYRROLOCHINAZOLINVERBINDUNGEN
EP2948457A4 (en) COMPOUNDS
GB201307331D0 (en) Compound
GB201408643D0 (en) Compound
EP3037100A4 (en) MEANS TO PREVENT MUSCLE ATROPHY
GB201306794D0 (en) Compounds
GB201322438D0 (en) Compound
GB201315772D0 (en) Compound
GB201305634D0 (en) Compound
GB201304250D0 (en) Compound
GB201322028D0 (en) Compounds
GB201301585D0 (en) Compound
GB201318323D0 (en) Compounds
GB201315253D0 (en) Compounds
GB201303572D0 (en) New Compound